STOCK TITAN

Turn Therapeutics (TTRX) Stock News, Feb-Jul 2026

TTRX NASDAQ

Turn Therapeutics Inc. (Nasdaq: TTRX) is a clinical-stage biotechnology company whose news flow centers on dermatology, advanced wound care, infectious disease therapies, and intranasal vaccine initiatives. Company updates frequently highlight progress in its lead program GX-03, a topical IL-36/IL-31 pathway inhibitor in a phase 2 trial for moderate to severe atopic dermatitis, as well as other late-stage clinical programs in eczema and onychomycosis.

News releases from Turn Therapeutics regularly cover clinical milestones, such as enrollment updates, safety summaries, and timing for interim and topline data from its phase 2 eczema study. Investors and observers can also follow announcements related to its thermostable intranasal vaccine initiative, including stability data for a live, lipid-enveloped vaccine formulated with the PermaFusion platform and the planned in-vivo and in-vitro studies for an intranasal influenza vaccine candidate.

Corporate and strategic developments are another key theme in TTRX news. The company has reported its direct listing on Nasdaq, capital strategy using flexible financing arrangements, and a global supply, development, and license agreement with Medline to develop and commercialize PermaFusion-based products in professional and retail markets. Governance updates, including the appointments of experienced board members and a Vice President of Corporate Communications, also feature prominently.

Turn Therapeutics additionally issues communications on shareholder engagement efforts, such as webinar series and public discussions involving its leadership on topics like healthcare communication and public trust in science. For readers tracking TTRX, this news page offers a centralized view of clinical progress, partnership activity, financing developments, and corporate governance changes over time.

Rhea-AI Summary

Turn Therapeutics (NASDAQ:TTRX) completed a comprehensive interim analysis of its adaptive Phase 2 trial of GX-03 in atopic dermatitis and finalized the Stage 2 design.

Data-supported changes include expansion to the full EASI severity spectrum, refined endpoints using the Hochberg procedure, and confirmation of a favorable safety and tolerability profile.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.27%
Tags
-
Rhea-AI Summary

Turn Therapeutics (NASDAQ:TTRX) will host a live webcast on July 7, 2026, at 4:30 p.m. ET to present key findings from a comprehensive interim analysis of its ongoing adaptive Phase 2 trial of GX-03 in atopic dermatitis.

The company will also outline an optimized Stage 2 design guiding completion of the Phase 2 program. The review of Stage 1 data was overseen by Dr. Bruce Stouch and Dr. Stephen Hahn. CEO Bradley Burnam and Dr. Hahn will host the webcast, with replay access available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
26.27%
Tags
none
-
Rhea-AI Summary

Turn Therapeutics (Nasdaq:TTRX) reported interim Phase 2 GX-03 data in moderate-to-severe atopic dermatitis from the first 50 completed subjects. At Week 4, 92.6% of GX-03 patients achieved EASI-50 vs 65.2% on vehicle; EASI-90 was 44.4% vs 30.4%, rising to 51.9% vs 34.8% by Week 8.

No treatment-related serious adverse events, tolerability issues, or discontinuations were observed. Interim findings are being used to refine enrollment criteria, endpoint hierarchy, and focus on earlier inflammatory endpoints as enrollment nears the original target. The company is preparing FDA interactions on regulatory pathways.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.73%
Tags
Rhea-AI Summary

Turn Therapeutics (Nasdaq:TTRX) reported a peer-reviewed publication in the Journal of Dermatological Treatment detailing GX-03 activity in an IL-36–associated Staphylococcus aureus-induced murine dermatitis model. GX-03 is the company’s lead program, currently in Phase 2 for moderate-to-severe atopic dermatitis.

Mice treated twice daily with GX-03 for seven days achieved a mean investigator global assessment score of 1.44 versus 3.00 in untreated controls (p = 0.0003), with no treatment-related adverse effects observed. The article is the first in a planned series exploring GX-03’s localized, non-systemic mechanism.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.31%
Tags
none
-
Rhea-AI Summary

Turn Therapeutics (Nasdaq:TTRX), a clinical-stage biotech focused on localized therapies for inflammatory skin diseases, will present at the Jefferies Global Healthcare Conference 2026 in New York City.

CEO Bradley Burnam presents on June 4, 2026, 9:55–10:25 AM EDT, with live and replay webcasts available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
none
-
Rhea-AI Summary

Turn Therapeutics (Nasdaq:TTRX) appointed Stephen M. Hahn, M.D., former FDA Commissioner, as executive clinical and regulatory lead.

He will oversee strategy for GX-03, an investigational topical therapy in a Phase 2 trial for moderate-to-severe atopic dermatitis and other inflammatory skin disease indications.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.99%
Tags
none
Rhea-AI Summary

Turn Therapeutics (Nasdaq:TTRX) reported Q1 2026 results and clinical progress. A Phase 2 trial of GX-03 in moderate-to-severe atopic dermatitis is ongoing, with interim data expected Q2 2026 and topline results mid-2026.

The company closed a growth capital facility with Avenue Capital providing access to up to $25 million in term loans, including an initial $7 million tranche. As of March 31, 2026, cash was $11.2 million versus $5.1 million at year-end 2025. Q1 2026 net loss was $971k versus $329k in Q1 2025, as operating expenses rose to $1.25 million. GX-03 is also being advanced toward a potential onychomycosis program.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
-
Rhea-AI Summary

Turn Therapeutics (Nasdaq: TTRX) reported full-year 2025 results and corporate updates. Key highlights: Phase 2 GX-03 topline expected mid-2026; secured a 42-month venture debt facility up to $25.0M with an initial $7.0M tranche; cash of $5.08M as of Dec 31, 2025 (excludes $7.0M); Medline supply and license agreement could enable revenue in late 2026. Financials: GAAP net loss of $3.19M, G&A of $5.59M, R&D of $0.27M, total assets $12.16M, and 27.72M weighted-average shares outstanding.

Board and leadership strengthened with appointments of Dr. Robert Redfield and Martin Dewhurst to support development, regulatory and strategic initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.66%
Tags
-
Rhea-AI Summary

Turn Therapeutics (Nasdaq: TTRX) entered a growth capital loan facility with Avenue Venture Opportunities Fund II for up to $25 million, including an initial $7 million tranche funded at closing and up to $18 million tied to clinical and corporate milestones.

Funds are expected to extend runway through the Phase 2 atopic dermatitis readout and, if fully drawn, through the end of 2027 while supporting registrational preparations for GX-03.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
Rhea-AI Summary

Turn Therapeutics (Nasdaq: TTRX) appointed Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory Affairs on February 17, 2026.

Dr. Redfield, former CDC director, will advise on clinical development, public health implications, and regulatory strategy for the company’s lead investigational therapy GX-03, currently in Phase 2 trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.83%
Tags
none

FAQ

What is the current stock price of Turn Therapeutics (TTRX)?

Turn Therapeutics (TTRX) last closed at $8.55.

What is the market cap of Turn Therapeutics (TTRX)?

The market cap of Turn Therapeutics (TTRX) is approximately $261.4M.